Literature DB >> 26762681

Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations.

Junya Kanda1, Ruta Brazauskas2, Zhen-Huan Hu3, Yachiyo Kuwatsuka4, Koji Nagafuji5, Heiwa Kanamori6, Yoshinobu Kanda1, Koichi Miyamura7, Makoto Murata8, Takahiro Fukuda9, Hisashi Sakamaki10, Fumihiko Kimura11, Sachiko Seo12, Mahmoud Aljurf13, Ayami Yoshimi14, Giuseppe Milone15, William A Wood16, Celalettin Ustun17, Shahrukh Hashimi18, Marcelo Pasquini3, Carmem Bonfim19, Jignesh Dalal20, Theresa Hahn21, Yoshiko Atsuta22, Wael Saber23.   

Abstract

The risk of acute graft-versus-host disease (GVHD) after HLA-matched sibling bone marrow transplantation (BMT) is lower in Japanese than in Caucasian patients. However, race may have differential effect on GVHD dependent on the graft source. North American Caucasian and Japanese patients receiving their first allogeneic BMT or peripheral blood stem cell transplantation from an HLA-matched sibling for leukemia were eligible. BMT was performed in 13% of the Caucasian patients and in 53% of the Japanese patients. On multivariate analysis, the interaction term between race and graft source was not significant in any of the models, indicating that graft source does not affect the impact of race on outcomes. The risk of grade III or IV acute GVHD was significantly lower in the Japanese patients compared with the Caucasian patients (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.57 to 0.96), which resulted in lower risk of nonrelapse mortality in the Japanese patients (HR, 0.69; 95% CI, 0.54 to 0.89). The risk of relapse was also lower in this group. The lower risks of nonrelapse mortality and relapse resulted in lower overall mortality rates among the Japanese patients. In conclusion, our data indicate that irrespective of graft source, the risk of severe acute GVHD is lower in Japanese patients, resulting in a lower risk of nonrelapse mortality.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone marrow transplantation; Graft-versus-host disease; Peripheral blood stem cell transplantation; Race

Mesh:

Year:  2016        PMID: 26762681      PMCID: PMC4801761          DOI: 10.1016/j.bbmt.2015.12.027

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  26 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.

Authors:  D Blaise; M Kuentz; C Fortanier; J H Bourhis; N Milpied; L Sutton; J P Jouet; M Attal; P Bordigoni; J Y Cahn; J M Boiron; M P Schuller; J P Moatti; M Michallet
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.

Authors:  Stephen Couban; David R Simpson; Michael J Barnett; Christopher Bredeson; Lothar Hubesch; Kang Howson-Jan; Tsiporah B Shore; Irwin R Walker; Peter Browett; Hans A Messner; Tony Panzarella; Jeffrey H Lipton
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 4.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

Authors:  K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

5.  Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group.

Authors:  Y Morishima; Y Morishita; M Tanimoto; R Ohno; H Saito; K Horibe; N Hamajima; K Naito; K Yamada; S Yokomaku
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

6.  Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.

Authors:  H T Hassan; M Stockschläder; B Schleimer; W Krüger; A R Zander
Journal:  Transpl Immunol       Date:  1996-12       Impact factor: 1.708

7.  Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease.

Authors:  Ingerid Weum Abrahamsen; Stig Sømme; Dag Heldal; Torstein Egeland; Dag Kvale; Geir Erland Tjønnfjord
Journal:  Haematologica       Date:  2005-01       Impact factor: 9.941

8.  Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations.

Authors:  Yachiyo Kuwatsuka; Yoshiko Atsuta; Mary M Horowitz; Jiro Inagaki; Junya Kanda; Koji Kato; Katsuyoshi Koh; Mei-Jie Zhang; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-10       Impact factor: 5.742

9.  Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.

Authors:  Norbert Schmitz; Meral Beksac; Dirk Hasenclever; Andrea Bacigalupo; Tapani Ruutu; Arnon Nagler; Eliane Gluckman; Nigel Russell; Jane F Apperley; Norbert C Gorin; Jeff Szer; Ken Bradstock; Agnes Buzyn; Peter Clark; Keith Borkett; Alois Gratwohl
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 10.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

View more
  13 in total

1.  Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation.

Authors:  K Kawamura; J Kanda; S Fuji; M Murata; K Ikegame; K Yoshioka; T Fukuda; Y Ozawa; N Uchida; K Iwato; T Sakura; M Hidaka; H Hashimoto; T Ichinohe; Y Atsuta; Y Kanda
Journal:  Bone Marrow Transplant       Date:  2017-07-17       Impact factor: 5.483

2.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

3.  Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database.

Authors:  Yuqian Sun; Eric Beohou; Myriam Labopin; Liisa Volin; Noel Milpied; Ibrahim Yakoub-Agha; Simona Piemontese; Emmanuelle Polge; Mohamed Houhou; Xiao-Jun Huang; Mohamad Mohty; Arnon Nagler; Norbert-Claude Gorin
Journal:  Haematologica       Date:  2016-04-14       Impact factor: 9.941

4.  Hematopoietic Cell Transplantation for Severe Combined Immunodeficiency Patients: a Japanese Retrospective Study.

Authors:  Satoshi Miyamoto; Katsutsugu Umeda; Mio Kurata; Akira Nishimura; Masakatsu Yanagimachi; Masataka Ishimura; Maho Sato; Tomonari Shigemura; Motohiro Kato; Yoji Sasahara; Akihiro Iguchi; Takashi Koike; Yoshiyuki Takahashi; Michiko Kajiwara; Masami Inoue; Yoshiko Hashii; Hiromasa Yabe; Koji Kato; Yoshiko Atsuta; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2021-08-27       Impact factor: 8.317

5.  Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.

Authors:  Yoshihiro Inamoto; Fumihiko Kimura; Junya Kanda; Junichi Sugita; Kazuhiro Ikegame; Hideki Nakasone; Yasuhito Nannya; Naoyuki Uchida; Takahiro Fukuda; Kosuke Yoshioka; Yukiyasu Ozawa; Ichiro Kawano; Yoshiko Atsuta; Koji Kato; Tatsuo Ichinohe; Masami Inoue; Takanori Teshima
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

6.  Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.

Authors:  Satoshi Kaito; Yujiro Nakajima; Konan Hara; Takashi Toya; Tetsuya Nishida; Naoyuki Uchida; Junichi Mukae; Takahiro Fukuda; Yukiyasu Ozawa; Masatsugu Tanaka; Kazuhiro Ikegame; Yuta Katayama; Takuro Kuriyama; Junya Kanda; Yoshiko Atsuta; Masao Ogata; Ayumi Taguchi; Kazuteru Ohashi
Journal:  Blood Adv       Date:  2020-03-24

7.  Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan.

Authors:  Tatsunori Goto; Takashi Tanaka; Masashi Sawa; Yasunori Ueda; Hiroatsu Ago; Shigeru Chiba; Heiwa Kanamori; Akinori Nishikawa; Masaharu Nougawa; Kazuteru Ohashi; Hirokazu Okumura; Mitsune Tanimoto; Takahiro Fukuda; Naomi Kawashima; Tomonori Kato; Kazuya Okada; Koji Nagafuji; Shin-Ichiro Okamoto; Yoshiko Atsuta; Masayuki Hino; Junji Tanaka; Koichi Miyamura
Journal:  Int J Hematol       Date:  2017-10-13       Impact factor: 2.490

Review 8.  Therapeutic uses of scleral contact lenses for ocular surface disease: patient selection and special considerations.

Authors:  Jennifer S Harthan; Ellen Shorter
Journal:  Clin Optom (Auckl)       Date:  2018-07-11

9.  Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients.

Authors:  Takahiko Nakane; Hiroshi Okamura; Yumi Tagaito; Shiro Koh; Takuro Yoshimura; Yosuke Makuuchi; Satoru Nanno; Mika Nakamae; Asao Hirose; Yasuhiro Nakashima; Hideo Koh; Masayuki Hino; Hirohisa Nakamae
Journal:  Int J Hematol       Date:  2019-09-27       Impact factor: 2.319

10.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Authors:  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.